Publication | Open Access

Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

Lymphoid NeoplasiaSingle ArmMedicineImmunologyAmc 085PathologyHivImmunotherapyOncologyBrentuximab Vedotin